维申医药科技

Wision Pharmaceuticals is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule drugs. The company's primary focus is on addressing chronic liver diseases, specifically chronic hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH), alongside inflammatory and autoimmune disorders. Its lead candidate, WS-016, is a next-generation HBV capsid assembly modulator currently undergoing Phase 2 clinical evaluation. Wision is backed by prominent life science investors including Qiming Venture Partners and Lilly Asia Ventures. The company aims to provide curative or highly effective treatments for patients with high unmet medical needs globally through its internal R&D engine.